Get the Stockscreener App
7.725
1.98%
0.145
Cullinan Therapeutics Inc stock is traded at $7.725, with a volume of 259.61K.
It is up +1.98% in the last 24 hours and up +3.76% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$7.58
Open:
$7.58
24h Volume:
259.61K
Relative Volume:
0.73
Market Cap:
$456.65M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.0935
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+5.96%
1M Performance:
+3.76%
6M Performance:
-18.89%
1Y Performance:
-54.29%
1-Day Range:
$7.58
$7.81
1-Week Range:
$6.91
$7.81
52-Week Range:
$6.85
$19.89
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
7.73 | 451.33M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.18 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.02 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.85 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.36 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.45 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Is now the right time to enter Cullinan Therapeutics Inc.July 2025 Technicals & Fast Entry Momentum Alerts - thegnnews.com
Is Cullinan Therapeutics Inc. on track to beat earningsJuly 2025 Snapshot & AI Driven Stock Movement Reports - thegnnews.com
Does Cullinan Therapeutics Inc. fit your quant trading modelQuarterly Performance Summary & Community Verified Watchlist Alerts - Newser
Technical Bounce Expected in Cullinan Therapeutics Inc. Next Week2025 Market Overview & Entry Point Confirmation Signals - sundaytimes.kr
How to build a custom watchlist for Cullinan Therapeutics Inc.July 2025 Setups & Free Accurate Trade Setup Notifications - Newser
Will Cullinan Therapeutics Inc. continue its uptrendAnalyst Upgrade & Risk Adjusted Buy/Sell Alerts - Newser
Cullinan Therapeutics Inc. Recovers — But Is It SustainableJuly 2025 Pullbacks & Stepwise Entry/Exit Trade Alerts - thegnnews.com
How to integrate Cullinan Therapeutics Inc. into portfolio analysis toolsJuly 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
How Cullinan Therapeutics Inc. stock performs during market volatilityWeekly Earnings Recap & AI Powered Buy/Sell Recommendations - Newser
Is Cullinan Therapeutics Inc. meeting your algorithmic filter criteria2025 Dividend Review & Weekly Market Pulse Updates - Newser
How to track smart money flows in Cullinan Therapeutics Inc.Trade Risk Assessment & Low Volatility Stock Suggestions - Newser
Using data models to predict Cullinan Therapeutics Inc. stock movement2025 Earnings Impact & Community Driven Trade Alerts - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Highlights & Consistent Growth Stock Picks - Newser
Insider Sellers Might Regret Selling Cullinan Therapeutics Shares at a Lower Price Than Current Market Value - simplywall.st
Technical signs of recovery in Cullinan Therapeutics Inc.2025 Major Catalysts & Capital Efficiency Focused Strategies - Newser
Cullinan Therapeutics Inc. Shows Risk Reward Favoring UpsideEarnings Growth Summary & AI Enhanced Execution Alerts - 선데이타임즈
Cullinan (CGEM) Q2 R&D Jumps 68% - AOL.com
Is Cullinan Therapeutics Inc. stock poised for growthFree Fundamental Winners With Safe Entry Plan - Newser
Is Cullinan Therapeutics Inc. showing signs of accumulationMonthly Long-Term Market Recap and Summary - Newser
Full technical analysis of Cullinan Therapeutics Inc. stockFree Swing Trade With Risk Management - Newser
Cullinan Therapeutics Inc. stock trend outlook and recovery pathProven Trading System with Consistent Gains - Newser
Market reaction to Cullinan Therapeutics Inc.’s recent newsTechnical Trade Plan with Entry Checklist - Newser
Is Cullinan Therapeutics Inc. stock reversal real or fakeEntry and Exit Strategy for Swing Traders - Newser
Clear Street Sees Favorable Read-Through for Cullinan Therapeutics' CLN-978 Trial in SjD Despite Novartis' Positive Phase 3 Results - AInvest
William Blair Has Pessimistic Outlook of CGEM Q3 Earnings - Defense World
Can swing trading help recover from Cullinan Therapeutics Inc. lossesEquity Performance Forecast Based on AI Models - Newser
Key resistance and support levels for Cullinan Therapeutics Inc.Free Value Investing Picks With Stability - Newser
Using Ichimoku Cloud for Cullinan Therapeutics Inc. technicalsDay Trading Setup and Momentum Analysis - Newser
Cullinan Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Cullinan Therapeutics Reports Q2 2025 Financial Results - TipRanks
What to expect from Cullinan Therapeutics Inc. in the next 30 daysPrice Movement and Market Sentiment Analysis - Newser
Cullinan Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c) - TipRanks
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):